GH Research (NASDAQ:GHRS) Price Target Lowered to $29.00 at Guggenheim

GH Research (NASDAQ:GHRS) had its price target decreased by Guggenheim from $32.00 to $29.00 in a research note released on Friday morning,Benzinga reports. Guggenheim currently has a buy rating on the stock.

Other research analysts have also issued research reports about the company. Cantor Fitzgerald began coverage on GH Research in a research report on Thursday, February 13th. They set an “overweight” rating and a $14.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of GH Research in a research note on Friday. Royal Bank of Canada started coverage on shares of GH Research in a research report on Friday, March 7th. They set an “outperform” rating and a $31.00 price target for the company. Finally, Stifel Nicolaus increased their price objective on shares of GH Research from $18.00 to $32.00 and gave the stock a “buy” rating in a report on Thursday, February 27th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $30.43.

GH Research Stock Down 3.5%

Shares of NASDAQ:GHRS opened at $10.42 on Friday. GH Research has a fifty-two week low of $6.00 and a fifty-two week high of $20.50. The firm has a 50-day simple moving average of $10.31 and a 200 day simple moving average of $9.87. The company has a market cap of $542.13 million, a PE ratio of -13.19 and a beta of 0.86.

GH Research (NASDAQ:GHRS) last issued its earnings results on Thursday, May 8th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.42. As a group, research analysts forecast that GH Research will post -0.8 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Jefferies Financial Group Inc. acquired a new stake in shares of GH Research in the first quarter valued at $8,272,000. Lynx1 Capital Management LP raised its holdings in shares of GH Research by 15.8% during the fourth quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company’s stock valued at $34,013,000 after acquiring an additional 663,100 shares during the period. Diadema Partners LP acquired a new stake in GH Research during the 4th quarter valued at $711,000. Woodline Partners LP boosted its position in GH Research by 112.0% during the 4th quarter. Woodline Partners LP now owns 78,949 shares of the company’s stock worth $553,000 after acquiring an additional 41,711 shares during the period. Finally, Millennium Management LLC purchased a new position in GH Research during the fourth quarter valued at approximately $145,000. Institutional investors and hedge funds own 56.90% of the company’s stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).